SI Group Announces CEO Leadership Transition

Marcello Boldrini Named Chief Executive Officer; David Bradley Departs Following Successful Tenure

THE WOODLANDS, Texas, Oct. 20, 2026 /PRNewswire/ -- SI Group, a leading global developer and manufacturer of performance additives, process solutions, and chemical intermediates, today announced the appointment of Marcello Boldrini as Chief Executive Officer, effective October 19, 2026. Boldrini succeeds David Bradley, who has served as President and Chief Executive Officer since 2019.

"We are pleased to welcome Marcello Boldrini as SI Group's next CEO," said Daryl Roberts, member of the SI Group Board of Directors. "Marcello brings significant experience in the global specialty chemicals industry and a strong track record of leading growth, transformation and operational improvement. His experience and perspective will serve SI Group well as we continue to strengthen our performance, serve our customers and execute our priorities."

Marcello Boldrini brings more than three decades of leadership experience in the specialty chemicals and materials industry, with a career spanning Europe, Asia and the Americas. Most recently, he served as Chief Executive Officer and a Director of Kraton Corporation, a Houston-based global specialty chemicals company. During his tenure at Kraton, Boldrini led growth and transformation initiatives, including the creation of a Transformation Office that generated more than $100 million in annual EBITDA improvements. Earlier in his career, he held senior leadership positions at Houghton International, Momentive/Hexion and Ashland. 

Boldrini resides in the Houston area and will be based at SI Group's headquarters in The Woodlands, Texas.

"I am honored to join SI Group as CEO and look forward to working with our employees, customers and partners," said Marcello Boldrini. "My initial focus will be on listening and learning, spending time with our teams and customers, and collaborating with the leadership team to build on SI Group's strengths and set clear priorities for the business. Safe and reliable operations, disciplined execution and delivering value for our customers will remain at the center of our work."

SI Group's leadership team will work closely with Boldrini to maintain a strong focus on safety, operational performance and customer commitments. Customers, suppliers and other business partners should continue to work through their existing SI Group contacts.

"On behalf of the Board, I want to thank David Bradley for his leadership and many contributions to SI Group," said Shawn Abrams, member of SI Group's Board of Directors. "David led SI Group through significant change and some of the most challenging conditions our industry has faced. During his tenure, the company successfully completed its 2025 recapitalization, strengthening SI Group's financial position and providing greater flexibility for the future. We are grateful for David's commitment to SI Group and its people, and we wish him continued success."

Customers, suppliers and other business partners should continue to work through their existing SI Group contacts.

About SI Group
SI Group is a global leader in performance additives, process solutions, and chemical intermediates. SI Group's chemistries are essential solutions that enhance the quality and performance of industrial and consumer goods in the plastics, rubber and adhesives, fuels, lubricants, coatings, and oilfield industries. Headquartered in The Woodlands, Texas, SI Group operates 18 manufacturing facilities across three continents and serves customers in more than 80 countries, supported by approximately 1,500 employees worldwide. Driven by a passion for safety, chemistry, sustainability, and delivering extraordinary results, SI Group innovates to create long-term value for a better future. Learn more at www.siigroup.com.

Media Contact:
Joseph Grande
ph: + 1.413.684.2463
joe@jgrandecommunications.com

** This press release is distributed by PR Newswire through automated distribution system, for which the client assumes full responsibility. **

SI Group Announces CEO Leadership Transition

Australians crack 6.87 billion eggs a year. Joint health research says we're throwing away the best bit.

SYDNEY, Oct. 20, 2026 /PRNewswire/ -- The paper-thin membrane inside every eggshell has been studied in human clinical trials for joint pain and stiffness. Now it's on supermarket shelves nationwide.

Vitaceuticals combines NEM with MagZorb magnesium glycinate in MagZorb Joint Ease with NEM, available nationally in major supermarkets and pharmacies, and on Amazon. For more information, visit Vitaceuticals' MagZorb Joint Ease page.

Natural eggshell membrane (NEM®) contains collagen, chondroitin and hyaluronic acid, compounds found in healthy cartilage. It has been tested in human clinical trials for more than 15 years.

The most striking result came from a double-blind, placebo-controlled study published in Clinical Rheumatology. ^[1,2] Adults with knee osteoarthritis took 500 mg of NEM daily. After just 10 days they reported 15.9% less joint pain than the placebo group, and the improvement held at two months. A 2018 placebo-controlled trial found post-menopausal women had less joint stiffness after exercise within a week.

"What stood out to me in the research was how early the change was measured: at day 10," said Sally Tadros, pharmacist and co-founder of Vitaceuticals. "That's a timeframe people can relate to."

The research lands as Australians rethink what's in their medicine cabinet. Current RACGP osteoarthritis guidelines suggest GPs don't offer long-time favourites like glucosamine and fish oil. Meanwhile, 4.1 million Australians live with arthritis, a number projected to hit 5.4 million by 2040. Women are hardest hit, with osteoarthritis about 80% more common in women than men.

"Most people have never heard of eggshell membrane, but it's one of the most interesting ingredients in joint health research right now," said Ms Tadros. "It's been hiding in plain sight in every kitchen, and most of us have been throwing it out with the shells."

Always read the label and follow the directions for use.

References

[1] The day-10 joint pain result (500 mg NEM vs placebo) Ruff KJ et al. "Eggshell membrane in the treatment of pain and stiffness from osteoarthritis of the knee: a randomized, multicenter, double-blind, placebo-controlled clinical study." Clin Rheumatol. 2009;28(8):907–914. DOI: 10.1007/s10067-009-1173-4 [2] The post-menopausal women and exercise stiffness result (2018) Ruff KJ et al. "Beneficial effects of natural eggshell membrane versus placebo in exercise-induced joint pain, stiffness, and cartilage turnover in healthy, postmenopausal women." Clin Interv Aging. 2018;13:285–295. DOI: 10.2147/CIA.S153782

[1] The day-10 joint pain result (500 mg NEM vs placebo)
Ruff KJ et al. "Eggshell membrane in the treatment of pain and stiffness from osteoarthritis of the knee: a randomized, multicenter, double-blind, placebo-controlled clinical study." Clin Rheumatol. 2009;28(8):907–914.
DOI: 10.1007/s10067-009-1173-4
[2] The post-menopausal women and exercise stiffness result (2018)
Ruff KJ et al. "Beneficial effects of natural eggshell membrane versus placebo in exercise-induced joint pain, stiffness, and cartilage turnover in healthy, postmenopausal women." Clin Interv Aging. 2018;13:285–295.
DOI: 10.2147/CIA.S153782

About Vitaceuticals

Vitaceuticals is an Australian health brand co-founded by pharmacist Sally Tadros, and winner of the Manufacturing category at the 2026 Australian Women's Small Business Champion Awards. vitaceuticals.com.au

NEM® is a registered trademark of Stratum Nutrition.

** This press release is distributed by PR Newswire through automated distribution system, for which the client assumes full responsibility. **

Vitaceuticals Launches MagZorb Joint Ease with NEM Nationwide